Efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis.
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 1, Pages 145-149
AbstractBackground: Vernal keratoconjunctivitis (VKC) is a chronic recurrent non-infectious allergic disease that generally affects children and young adults. The present study was conducted to assess efficacy of topical 0.05% cyclosporine in Vernalkeratoconjunctivitis. Materials & Methods:86 patients diagnosed with Vernalkeratoconjunctivitis (VKC) of both genderswere enrolled. All were prescribed topical 0.05% cyclosporine 4 times a day. Patients underwent complete ophthalmic examination and symptoms and signs and intraocular pressure using non contact tonometer. The patients were evaluated at weeks 4, 8 and 12 after the initiation of therapy. Symptoms and signs before and after treatment, during the four-week intervals, were recorded and scores between 0 and 3 were assigned. Results: Out of 86 patients, males were 56 and females were 30. Median of symptoms score at baseline was 11, at 4 weeks were 4, at 8 weeks were 5 and at 12 weeks were 4. Sign score at baseline was 6, at 4 weeks were 4, at 8 weeks were 3 and at 12 weeks were 3. The difference was significant (P< 0.05). Conclusion: Topical cyclosporine 0.05% help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC.
- Article View: 22
- PDF Download: 0